Figure 5.

IQUB activates Wnt/β‐catenin signaling pathway via Akt/GSK3β pathway. A, Proteasomes inhibitor MG‐132 reverses the effect of IQUB knockdown on β‐catenin degradation. B, Inhibiting GSK3β kinase activity by Licl reduces inhibition of β‐catenin expression by IQUB knockdown. siR‐IQUB or siR‐NC was transfected into MDA‐MB‐231 cells. 36 h after transfection, the cells were treated with 30 mmol/L Licl for 12 h and then harvested for Western blotting analysis to detect the expression of GFP‐β‐catenin, p‐GSK3β (S9) and IQUB. C, Licl reverses the effect of IQUB knockdown on inhibitory activity of Wnt/β‐catenin signaling pathway. siR‐IQUB or siR‐NC was transfected into MDA‐MB‐231 cells. 36 h after transfection, the cells were treated with 30 mmol/L Licl for 12 h and harvested for luciferase activity assay. D, MDA‐MB‐231 cells were transfected with flag‐NC and flag‐IQUB, treated with Licl for 48 h and harvested for Western blot assay. E, MDA‐MB‐231 cells were transfected with flag‐NC and flag‐IQUB, treated with Licl for 48 h and harvested for TOP/FOP flash assay. F, Akt inhibitor MK2206 (0.1 μmol/L) reduces effect of IQUB overexpression on the expression of p‐Akt (S473), p‐GSK3β (S9), and β‐catenin. G, Akt inhibitor MK2206 (0.1 μmol/L) reduces effect of IQUB overexpression on the activity of Wnt/β‐catenin signaling pathway. **P < .01, ***P < .001, ns represents no statistical significance